MARATTO

article · Egyptian Journal of Chemistry

Some novel heterocyclic systems using 3-formylchromone: Synthesis and antimicrobial efficiency

20241 citationAin Shams University

Abstract

The electron deficient precursor 3 was synthesized by condensation of acetyl derivative 2 with 3-formylchromone (1). Compound 3 reacted with a range of binucleophilic reagents in order to build a variety of heterocyclic systems and explore the reactivity of different electron-deficient sites. Reaction of compound 3 with phenylhydrazine afforded dipyrazole derivative through reaction with both γ-pyrone moieties. Similarly, a variety of dipyrimidines were synthesized by reacting precursor 3 with some 1,3-N,N-binucleophiles. Further, a range of seven-heterocyclic systems, including dibenzodiazepine, dibenzoxazepine and dibenzothiazepine were generated from treating compound 3 with a variety of 1,4-binucleophiles, including o-phenylenediamine, o-aminophenol and o-aminothiophenol, respectively. Reaction of substrate 3 with two carbon nucleophiles namely cyanoacetamide and ethyl cyanoacetate furnished dipyridine 12 and dipyran 13, respectively. The synthesized compounds' antimicrobial efficacy demonstrated a noteworthy inhibitory effect on the growth of microorganisms under investigation. Spectral and analytical data of the synthesized compounds were used to confirm their structures.

Research topics

  • Synthesis of Organic Compounds
  • Synthesis and biological activity
  • Synthesis and Characterization of Heterocyclic Compounds

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ejchem.2024.261988.9172

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.